The UK has invested hundreds of millions of pounds in the development and procurement of vaccines against COVID-19.
In April 2020, the UK government announced a £84 million investment in the Oxford University vaccine, which is now known as the AstraZeneca vaccine. This investment was made in order to accelerate the development and production of the vaccine.
In August 2020, the UK Government announced a further £93 million investment in the Oxford vaccine. This investment was to support the clinical studies, manufacturing, and delivery of the vaccine.
In July 2020, the UK government also announced a £48 million investment in the Novavax vaccine. This investment was made to support clinical studies, manufacturing, and delivery of the vaccine.
In October 2020, the UK government announced a further £42 million investment in the Novavax vaccine. This investment was made to support the clinical studies, manufacturing, and delivery of the vaccine.
In total, the UK government has invested over £267 million in the development and procurement of COVID-19 vaccines. This investment has enabled the UK to be one of the first countries in the world to have access to a safe and effective vaccine against the virus.